Zacks: CSPC Pharmaceutical Group Ltd (CHPTY) Given Average Recommendation of “Strong Buy” by Analysts
CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Zacks has also assigned CSPC Pharmaceutical Group an industry rank of 163 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research lowered shares of CSPC Pharmaceutical Group from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th.
CSPC Pharmaceutical Group (NASDAQ:CHPTY) traded up 9.24% during midday trading on Tuesday, hitting $80.04. The company had a trading volume of 43 shares. The firm has a market capitalization of $9.69 billion and a P/E ratio of 32.02. The company has a 50 day moving average price of $80.04 and a 200 day moving average price of $73.39. CSPC Pharmaceutical Group has a 1-year low of $51.03 and a 1-year high of $80.04.
CSPC Pharmaceutical Group Company Profile
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with MarketBeat.com's FREE daily email newsletter.